Related Experiment Video
Updated: Aug 13, 2026
09:54
Comprehensive Profiling of Dopamine Regulation in Substantia Nigra and Ventral Tegmental Area
Published on: August 10, 2012
Catechol-O-methyltransferase activity: a determinant of levodopa response
Clinical Pharmacology and Therapeutics
|August 1, 1980
Summary
Higher erythrocyte catechol-O-methyltransferase activity in Parkinson's patients correlates with poorer levodopa response. This enzyme activity may significantly influence treatment effectiveness.
Area of Science:
- Pharmacology
- Neuroscience
- Biochemistry
Background:
- Parkinson's disease (PD) is a neurodegenerative disorder impacting motor function.
- Levodopa is a primary treatment, but its efficacy varies.
- Catechol-O-methyltransferase (COMT) metabolizes levodopa.
Purpose of the Study:
- To investigate the relationship between erythrocyte COMT activity and levodopa pharmacokinetics/clinical response in PD patients.
- To determine if erythrocyte COMT activity is a predictor of levodopa treatment outcomes.
Main Methods:
- Assessed erythrocyte catechol-O-methyltransferase (COMT) activity in 14 Parkinson's disease patients.
- Measured plasma concentrations of levodopa and its metabolite 3-O-methyldopa.
- Correlated COMT activity with plasma concentration ratios and clinical response to levodopa.
Main Results:
- Erythrocyte COMT activity correlated with plasma 3-O-methyldopa/levodopa ratios.
- Higher erythrocyte COMT activity was associated with less favorable clinical responses to levodopa.
- This suggests erythrocyte COMT activity reflects COMT activity in key metabolic tissues.
Conclusions:
- Erythrocyte COMT activity is a significant determinant of levodopa response in Parkinson's disease.
- Measuring erythrocyte COMT activity could help personalize levodopa therapy.
- Further research is warranted to explore therapeutic strategies targeting COMT.
Related Concept Videos
01:08Allosteric Regulation
Allosteric regulation of enzymes occurs when the binding of an effector molecule to a site that is different from the active site causes a change in the enzymatic activity. This alternate site is called an allosteric site, and an enzyme can contain more than one of these sites. Allosteric regulation can either be positive or negative, resulting in an increase or decrease in enzyme activity. Most enzymes that display allosteric regulation are metabolic enzymes involved in the degradation or...
01:22Direct-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship
Cholinergic agonists or cholinomimetics mimic the action of acetylcholine to stimulate the parasympathetic nervous system. They are categorized into direct-acting and indirect-acting agents. The direct-acting cholinergic drugs induce the parasympathetic response by directly binding to the muscarinic or nicotine receptors. In comparison, the indirect-acting cholinergic drugs prevent acetylcholine hydrolysis, indirectly contributing to the extended parasympathetic response.
The direct-acting...
The direct-acting...
01:24Parkinson's Disease: Treatment
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
01:17Phase II Reactions: Methylation Reactions
Methylation is a phase II biotransformation process involving the attachment of a methyl group to a substrate. Enzymes known as methyltransferases orchestrate this reaction.
The mechanism of methylation unfolds in two stages. The first stage sees a methyltransferase enzyme facilitating the transfer of a methyl group from S-adenosylmethionine (SAM) to the substrate, forming S-adenosylhomocysteine (SAH). The second stage involves further metabolism of SAH into homocysteine, which can be recycled...
The mechanism of methylation unfolds in two stages. The first stage sees a methyltransferase enzyme facilitating the transfer of a methyl group from S-adenosylmethionine (SAM) to the substrate, forming S-adenosylhomocysteine (SAH). The second stage involves further metabolism of SAH into homocysteine, which can be recycled...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...